4:47 PM
Jun 03, 2014
 |  BC Extra  |  Company News

EMA to review Vanda's Hetlioz

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) said EMA accepted for review an MAA for Hetlioz...

Read the full 53 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >